Connection

Raymond Anton to Narcotic Antagonists

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Narcotic Antagonists.
Raymond Anton
Connection Strength
6.820
Narcotic Antagonists
  1. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.727
  2. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
    View in: PubMed
    Score: 0.539
  3. Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study. Addiction. 2013 Oct; 108(10):1745-6.
    View in: PubMed
    Score: 0.422
  4. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res. 2012 Mar; 36(3):385-94.
    View in: PubMed
    Score: 0.365
  5. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.354
  6. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008 Aug 14; 359(7):715-21.
    View in: PubMed
    Score: 0.295
  7. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008 Jun; 9(6):655-8.
    View in: PubMed
    Score: 0.291
  8. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
    View in: PubMed
    Score: 0.287
  9. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
    View in: PubMed
    Score: 0.285
  10. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
    View in: PubMed
    Score: 0.269
  11. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17.
    View in: PubMed
    Score: 0.252
  12. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005 Oct; 15(5):723-8.
    View in: PubMed
    Score: 0.242
  13. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
    View in: PubMed
    Score: 0.239
  14. Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep. 2004 Oct; 6(5):332-8.
    View in: PubMed
    Score: 0.226
  15. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
    View in: PubMed
    Score: 0.215
  16. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003; 12(s1):s53-s68.
    View in: PubMed
    Score: 0.200
  17. Naltrexone for alcohol dependence: comments on Morris et al. (2001). Addiction. 2001 Dec; 96(12):1855.
    View in: PubMed
    Score: 0.186
  18. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
    View in: PubMed
    Score: 0.164
  19. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
    View in: PubMed
    Score: 0.161
  20. Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
    View in: PubMed
    Score: 0.128
  21. Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
    View in: PubMed
    Score: 0.125
  22. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
    View in: PubMed
    Score: 0.105
  23. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
    View in: PubMed
    Score: 0.100
  24. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.096
  25. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
    View in: PubMed
    Score: 0.075
  26. The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J Stud Alcohol. 2006 Sep; 67(5):700-6.
    View in: PubMed
    Score: 0.065
  27. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl. 2005 Jul; (15):56-64; discussion 33.
    View in: PubMed
    Score: 0.059
  28. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
    View in: PubMed
    Score: 0.045
  29. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
    View in: PubMed
    Score: 0.043
  30. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
    View in: PubMed
    Score: 0.041
  31. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
    View in: PubMed
    Score: 0.038
  32. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res. 1996 Aug; 20(5):841-6.
    View in: PubMed
    Score: 0.032
  33. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol. 1996 Mar; 31 Suppl 1:43-53.
    View in: PubMed
    Score: 0.031
  34. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol Suppl. 1996 Mar; 31(1):43-53.
    View in: PubMed
    Score: 0.031
  35. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. J Stud Alcohol Drugs. 2014 Mar; 75(2):335-46.
    View in: PubMed
    Score: 0.027
  36. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
    View in: PubMed
    Score: 0.025
  37. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.025
  38. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999 Sep; 23(9):1484-91.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.